A micrograph of urothelial carcinoma, the most common type of bladder cancer. Stanford Medicine researchers and colleagues have developed a urine test that measures RNA shed by tumor cells to detect bladder cancer and help guide treatment decisions. | Getty Images

New urine test could improve bladder cancer diagnosis

En: ,

The article published by Stanford University presents a new urine-based diagnostic test developed by researchers at Stanford Medicine and the VA Palo Alto Health Care System. This technology, known as uRARE-seq, aims to improve the detection and monitoring of bladder cancer through the analysis of RNA fragments released by tumor cells into urine. Unlike conventional diagnostic methods that primarily examine DNA mutations, this approach analyzes gene activity, providing information about both the presence of cancer and its biological behavior.

The researchers evaluated the effectiveness of the test using 683 urine samples collected from patients and healthy volunteers. Results demonstrated that uRARE-seq successfully identified 95% of patients with localized bladder cancer and correctly classified 90% of individuals without the disease. Additionally, the test performed better than conventional urine cytology and DNA-based testing methods. These findings suggest that RNA analysis could become a valuable tool for detecting bladder cancer while reducing the need for certain invasive diagnostic procedures.

Another important contribution of this research is its potential to guide personalized cancer treatments. By examining RNA patterns, scientists identified biological characteristics associated with patients’ responses to immunotherapy, particularly Bacillus Calmette-Guérin (BCG) treatment. The technology also demonstrated the ability to detect remaining cancer cells after surgery or treatment. This information could eventually help physicians determine whether immunotherapy or chemotherapy would be more appropriate for individual patients, improving treatment decisions and potentially avoiding unnecessary interventions.

Finally, the article emphasizes the importance of developing noninvasive diagnostic technologies in modern medicine. Bladder cancer frequently requires continuous monitoring because of its high recurrence rate, making reliable and accessible testing particularly valuable. Although uRARE-seq has demonstrated promising results, further clinical studies involving larger patient populations are necessary before its routine medical implementation. This research represents an important advancement in molecular diagnostics and personalized medicine, highlighting the potential of RNA-based technologies to improve cancer detection, treatment monitoring, and patient care.

Read more: DOWNLOAD

Reference